ProKidney Corp Ordinary Shares - Class A PROK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $1.80
- Day Range
- $1.70–1.78
- 52-Week Range
- $1.53–5.45
- Bid/Ask
- $1.77 / $1.79
- Shares Outstanding
- 205.20M
- Market Cap
- $361.15M
- Volume/Avg
- 936,948 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 302.00
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 231
- Website
- https://www.prokidney.com
Valuation
|
Metric
|
PROK
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 302.00 |
Price/Cash Flow | — |
Price/Earnings
PROK
Financial Strength
|
Metric
|
PROK
|
|---|---|
Quick Ratio | 8.71 |
Current Ratio | 9.06 |
Interest Coverage | −8,871.16 |
Quick Ratio
PROK
Profitability
|
Metric
|
PROK
|
|---|---|
Return on Assets (Normalized) | −38.13% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −45.35% |
Return on Assets
PROK
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<XFTl% | LOCK|rRV!$ | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|tX<bd%d | LOCK|SnCF | $70B | |||
| argenx SE ADR
ARGX
| LOCK|?X#F<< | LOCK|^zw | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|r@$#!y> | LOCK|!&P!Z | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|p<HdMq | LOCK|TcN | $36B | |||
| Moderna Inc
MRNA
| LOCK|dQw$$F | LOCK|ZY | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<#G#P<P | LOCK|YgL@> | $25B | |||
| Incyte Corp
INCY
| LOCK|<yK^Vs | LOCK|w> | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|$JXMJML | LOCK|wd | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|R&#h^f? | LOCK|W^ | $17B |
United States